Top Markets
#1 ADO Protocol ADO Protocol +194.54%
#2 Islamic Coin Islamic Coin +155.33%
#3 GoPlus Security GoPlus Security +40.11%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.36%
#6 Wrapped NXM Wrapped NXM +14.17%
#7 Verus Coin Verus Coin +13.65%
#8 Casper Network Casper Network +13.15%
#9 Pons Pons +12.20%
#10 o1.exchange o1.exchange +12.20%
Coin of the day
ADO Protocol ADO Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Apimeds Pharmaceuticals US, Inc Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUS
Clasificación en acciones #33687
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Precio por acción
$4.70
Última sincronización: 2026-08-14
Capitalización bursátil
$7.09M
Cambio (1 día)
-0.21%
Cambio (1 año)
-70.63%
País
US
Comercio Apimeds Pharmaceuticals US, Inc (APUS)

Categoría

Healthcare
Ganancias de Apimeds Pharmaceuticals US, Inc (APUS)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Apimeds Pharmaceuticals US, Inc, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Apimeds Pharmaceuticals US, Inc desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE